METTL3 and prostate adenocarcinoma: While CNA were rare in primary prostate adenocarcinoma samples (~1% of cases), METTL3 CNA were more common in metastatic adenocarcinoma samples (~3% of cases), and NEPC (~17% of cases) (Figure 1A).